Index - P/E - EPS (ttm) -6.16 Insider Own 5.96% Shs Outstand 93.73M Perf Week 9.76%
Market Cap 11.91B Forward P/E 12.42 EPS next Y 10.22 Insider Trans 0.92% Shs Float 88.26M Perf Month -2.56%
Income -535.98M PEG - EPS next Q 0.01 Inst Own 86.71% Short Float 5.52% Perf Quarter 6.88%
Sales 1.24B P/S 9.58 EPS this Y 140.46% Inst Trans 6.40% Short Ratio 5.83 Perf Half Y 18.33%
Book/sh 9.17 P/B 13.84 EPS next Y 335.49% ROA -16.77% Short Interest 4.87M Perf Year 2.92%
Cash/sh 17.86 P/C 7.11 EPS next 5Y - ROE -86.15% 52W Range 55.25 - 159.89 Perf YTD 31.60%
Dividend Est. - P/FCF - EPS past 5Y -1.21% ROI -25.13% 52W High -20.63% Beta 0.94
Dividend TTM - Quick Ratio 3.45 Sales past 5Y 32.89% Gross Margin 84.34% 52W Low 129.68% ATR (14) 3.94
Dividend Ex-Date - Current Ratio 3.95 EPS Y/Y TTM 24.04% Oper. Margin -21.54% RSI (14) 58.49 Volatility 4.56% 3.03%
Employees 1314 Debt/Eq 1.63 Sales Y/Y TTM 33.26% Profit Margin -43.11% Recom 1.48 Target Price 166.26
Option/Short Yes / Yes LT Debt/Eq 1.48 EPS Q/Q 134.77% Payout - Rel Volume 0.23 Prev Close 127.39
Sales Surprise 2.48% EPS Surprise 582.15% Sales Q/Q 53.54% Earnings Feb 28 AMC Avg Volume 835.55K Price 126.90
SMA20 3.09% SMA50 0.77% SMA200 13.78% Trades
Volume 19,098 Change -0.38%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-31-24 Initiated BMO Capital Markets
Outperform
$170
Dec-13-23 Resumed Citigroup
Buy
$113
Dec-12-23 Initiated Deutsche Bank
Buy
$109
Nov-21-23 Initiated Wedbush
Outperform
$224
Oct-31-23 Downgrade Oppenheimer
Outperform → Perform
Oct-31-23 Downgrade Cantor Fitzgerald
Overweight → Neutral
$166 → $40
Jun-23-23 Downgrade Evercore ISI
Outperform → In-line
$139
Apr-26-23 Initiated SMBC Nikko
Outperform
$185
Apr-04-23 Initiated Citigroup
Buy
$179
Mar-01-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$141 → $187
Dec-22-22 Reiterated BTIG Research
Buy
$125 → $160
Dec-16-22 Upgrade UBS
Neutral → Buy
$100 → $158
Apr-04-22 Resumed Cantor Fitzgerald
Overweight
$140
Jan-05-22 Reiterated Needham
Buy
$157 → $150
Dec-09-21 Upgrade Oppenheimer
Perform → Outperform
$125
Nov-05-21 Upgrade JP Morgan
Neutral → Overweight
$130
Sep-15-21 Upgrade Guggenheim
Neutral → Buy
Aug-05-21 Upgrade JP Morgan
Underweight → Neutral
$92 → $87
Jun-15-21 Initiated BTIG Research
Buy
$110
Apr-26-21 Resumed Credit Suisse
Neutral
$72
Show Previous Ratings
Apr-24-24 08:30AM
Apr-13-24 09:39PM
Apr-08-24 04:13PM
(Investor's Business Daily)
Apr-06-24 08:45AM
Apr-02-24 07:04AM
04:00PM
Loading…
Mar-29-24 04:00PM
11:30AM
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
09:47AM
Loading…
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Feb-28-24 06:00PM
04:23PM
(Associated Press Finance)
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
10:00AM
Loading…
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Nov-09-23 10:00AM
Nov-08-23 10:15AM
Nov-07-23 11:23PM
Nov-02-23 06:25PM
12:18PM
08:30AM
12:00AM
Nov-01-23 05:03PM
(Associated Press Finance) +13.68%
04:29PM
04:05PM
Oct-31-23 07:02PM
04:19PM
04:07PM
(Investor's Business Daily)
03:03PM
(The Wall Street Journal)
11:52AM
10:26AM
10:21AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boor Kathryn Jean Director Mar 11 '24 Sale 122.93 761 93,550 7,516 Mar 11 08:00 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Option Exercise 13.90 15,000 208,500 37,840 Mar 11 08:02 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Sale 123.25 15,000 1,848,795 22,840 Mar 11 08:02 PM Mayo Stephen Director Mar 05 '24 Sale 122.96 3,135 385,480 6,621 Mar 06 08:00 PM Arif Bilal Chief Tech Ops Officer Mar 01 '24 Sale 128.84 2,000 257,676 26,836 Mar 05 08:00 PM Brown Ryan Edward EVP, General Counsel Mar 01 '24 Sale 125.34 2,000 250,680 31,827 Mar 05 08:00 PM Estepan Ian Michael Chief Financial Officer Mar 01 '24 Sale 128.30 1,200 153,960 39,114 Mar 05 08:00 PM BEHRENS M KATHLEEN Director Nov 03 '23 Option Exercise 29.03 15,000 435,450 174,993 Nov 06 08:00 AM Barry Richard Director Nov 03 '23 Buy 78.81 50,000 3,940,500 140,000 Nov 06 08:00 AM INGRAM DOUGLAS S President & CEO Nov 03 '23 Buy 79.36 25,225 2,001,800 390,307 Nov 06 08:00 AM Chambers Michael Andrew Director Aug 14 '23 Buy 109.47 9,979 1,092,429 246,996 Aug 15 08:00 AM Chambers Michael Andrew Director Aug 11 '23 Buy 108.05 23,686 2,559,272 237,017 Aug 14 08:00 AM Chambers Michael Andrew Director Aug 10 '23 Buy 106.15 34,867 3,701,067 213,331 Aug 11 07:40 AM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Option Exercise 29.03 15,000 435,450 35,994 Aug 08 08:00 PM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Sale 106.72 15,000 1,600,800 20,994 Aug 08 08:00 PM
Index RUT P/E - EPS (ttm) -4.82 Insider Own 64.42% Shs Outstand 33.18M Perf Week 4.17%
Market Cap 442.12M Forward P/E - EPS next Y -2.81 Insider Trans 2.33% Shs Float 20.97M Perf Month -19.09%
Income -246.42M PEG - EPS next Q -0.81 Inst Own 38.33% Short Float 25.02% Perf Quarter -29.44%
Sales 2.13M P/S 207.57 EPS this Y 33.23% Inst Trans -0.70% Short Ratio 19.03 Perf Half Y 67.04%
Book/sh 3.46 P/B 2.17 EPS next Y 10.79% ROA -52.60% Short Interest 5.25M Perf Year -31.07%
Cash/sh 5.74 P/C 1.31 EPS next 5Y - ROE -100.48% 52W Range 3.81 - 17.70 Perf YTD -9.75%
Dividend Est. - P/FCF - EPS past 5Y -44.65% ROI -103.58% 52W High -57.63% Beta 0.32
Dividend TTM - Quick Ratio 8.18 Sales past 5Y 19.85% Gross Margin -413.85% 52W Low 96.85% ATR (14) 0.86
Dividend Ex-Date - Current Ratio 8.18 EPS Y/Y TTM 10.38% Oper. Margin -12369.06% RSI (14) 38.76 Volatility 12.51% 9.78%
Employees 224 Debt/Eq 0.20 Sales Y/Y TTM 99.25% Profit Margin -11568.83% Recom 1.89 Target Price 21.22
Option/Short Yes / Yes LT Debt/Eq 0.17 EPS Q/Q 14.63% Payout - Rel Volume 0.87 Prev Close 7.65
Sales Surprise -6.93% EPS Surprise 0.11% Sales Q/Q 75.00% Earnings Mar 07 AMC Avg Volume 275.71K Price 7.50
SMA20 -11.52% SMA50 -29.17% SMA200 -12.19% Trades
Volume 24,258 Change -1.96%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-24 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed Jefferies
Buy
$61 → $55
Oct-17-22 Initiated JP Morgan
Neutral
$27
Aug-29-22 Initiated BofA Securities
Buy
$34
Dec-13-21 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade Wedbush
Neutral → Outperform
Aug-26-21 Initiated Morgan Stanley
Overweight
$100
Jan-29-21 Initiated RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade Wedbush
Outperform → Neutral
Jul-17-20 Initiated Robert W. Baird
Outperform
$90
Jul-01-20 Initiated H.C. Wainwright
Buy
$88
May-28-20 Initiated SunTrust
Buy
$86
Apr-22-20 Initiated Wedbush
Outperform
$73
Oct-14-19 Initiated Stifel
Buy
$32
Oct-14-19 Initiated Piper Jaffray
Overweight
$26
Oct-14-19 Initiated Jefferies
Buy
$25
Oct-14-19 Initiated Guggenheim
Buy
$30
Show Previous Ratings
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
09:55AM
Loading…
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
02:46AM
Loading…
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
05:25PM
Loading…
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
08:54AM
07:59AM
07:41AM
06:01AM
02:00AM
Feb-09-22 03:34PM
07:00AM
Feb-03-22 04:05PM
Jan-10-22 10:00AM
Jan-05-22 07:00AM
Dec-13-21 09:43AM
07:08AM
Dec-11-21 01:31PM
Dec-09-21 07:36AM
Dec-08-21 07:00AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BAKER BROS. ADVISORS LP Director Mar 28 '24 Buy 9.62 97,473 937,632 3,753,480 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 27 '24 Buy 9.24 27,844 257,170 3,664,073 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 26 '24 Buy 8.26 270,000 2,230,767 3,638,533 Mar 28 07:04 PM Schwarzer Fred CEO AND PRESIDENT Mar 14 '24 Sale 10.17 4,182 42,533 216,651 Mar 15 07:51 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '24 Sale 10.17 2,543 25,864 90,418 Mar 15 07:53 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 14 '24 Sale 10.17 2,535 25,782 94,388 Mar 15 07:55 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 14 '24 Sale 10.17 1,844 18,754 171,856 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '24 Sale 10.17 1,578 16,049 61,006 Mar 15 07:48 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '24 Sale 10.17 464 4,719 26,507 Mar 15 07:57 PM Schwarzer Fred CEO AND PRESIDENT Mar 13 '24 Sale 9.88 4,765 47,055 220,833 Mar 15 07:51 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 13 '24 Sale 9.88 2,897 28,608 92,961 Mar 15 07:53 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.88 2,889 28,529 96,923 Mar 15 07:55 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 13 '24 Sale 9.88 2,101 20,748 173,700 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 13 '24 Sale 9.88 1,798 17,756 62,584 Mar 15 07:48 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 13 '24 Sale 9.88 529 5,224 26,971 Mar 15 07:57 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 01 '24 Option Exercise 0.93 3,026 2,814 4,039 Mar 05 07:34 PM BAKER BROS. ADVISORS LP Director Dec 15 '23 Buy 6.55 288,007 1,887,531 3,390,323 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 6.50 157,370 1,023,157 3,123,585 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 5.96 87,316 520,776 2,977,836 Dec 15 05:32 PM Schwarzer Fred CEO and President Dec 13 '23 Sale 5.78 17,576 101,558 102,848 Dec 15 07:20 PM Keyt Bruce Chief Scientific Officer Dec 13 '23 Sale 5.78 7,574 43,764 129,551 Dec 15 07:19 PM Decker Lisa Lynn Chief Business Officer Dec 13 '23 Sale 5.78 4,369 25,245 35,632 Dec 15 07:18 PM Takimoto Chris H Chief Medical Officer Nov 29 '23 Sale 6.21 1,180 7,331 53,562 Dec 01 07:03 PM Decker Lisa Lynn Chief Business Officer Nov 29 '23 Sale 6.21 1,180 7,331 40,001 Dec 01 07:01 PM Gauthier George Chief Commercial Officer Nov 29 '23 Sale 6.21 1,180 7,331 39,642 Dec 01 07:02 PM Tahir Misbah Chief Financial Officer Nov 27 '23 Sale 5.06 1,337 6,764 49,608 Nov 29 08:49 PM Schwarzer Fred CEO and President Nov 27 '23 Sale 5.06 1,337 6,764 120,424 Nov 29 08:48 PM Keyt Bruce Chief Scientific Officer Nov 27 '23 Sale 5.06 933 4,720 137,125 Nov 29 08:47 PM Gauthier George Chief Commercial Officer Oct 02 '23 Sale 7.95 935 7,430 39,082 Oct 03 07:55 PM Gauthier George Chief Commercial Officer Jul 03 '23 Sale 9.42 936 8,818 40,017 Jul 05 09:08 PM Topsoe Jakob Haldor Director Jun 30 '23 Buy 9.25 3,500 32,375 81,644 Jul 03 06:46 PM Topsoe Christina Teng Director Jun 30 '23 Buy 9.32 3,000 27,957 9,800 Jul 05 09:07 PM Redmile Group, LLC Director Jun 29 '23 Buy 9.42 80,423 757,585 2,974,186 Jul 03 09:45 PM Topsoe Jakob Haldor Director Jun 29 '23 Buy 9.10 3,500 31,846 78,144 Jul 03 06:46 PM Redmile Group, LLC Director Jun 29 '23 Sale 9.42 80,423 757,585 2,893,763 Jul 03 09:45 PM BEHRENS M KATHLEEN Director Jun 26 '23 Buy 8.00 112,500 900,000 330,700 Jun 28 07:34 PM Gauthier George Chief Commercial Officer May 23 '23 Sale 12.31 1,259 15,497 40,953 May 25 07:20 PM Decker Lisa Lynn Chief Business Officer May 23 '23 Sale 12.31 1,259 15,497 41,181 May 25 07:20 PM Tahir Misbah Chief Financial Officer May 23 '23 Sale 12.31 1,259 15,497 50,711 May 25 07:23 PM Takimoto Chris H Chief Medical Officer May 23 '23 Sale 12.31 1,259 15,497 54,742 May 25 07:24 PM Schwarzer Fred CEO and President May 23 '23 Sale 12.31 1,259 15,497 121,761 May 25 07:22 PM Keyt Bruce Chief Scientific Officer May 23 '23 Sale 12.31 982 12,088 138,058 May 25 07:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
